Diagnosis of precancerous lesions of the breast

The purpose of this work is to determine the optimal markers for clarifying the degree of proliferative activity in benign breast lesions, which can be used in surgical treatment planning. Materials and methods. The immunocytochemical results of tumor proliferation marker (Ki-67), cancer-embryoni...

Full description

Saved in:
Bibliographic Details
Main Authors: D. I. Kebalo, N. P. Miroshnykova, O. P. Shershniova, S. M. Pashchenko, E. D. Zvantseva
Format: Article
Language:English
Published: Zaporizhzhia State Medical and Pharmaceutical University 2020-06-01
Series:Zaporožskij Medicinskij Žurnal
Subjects:
Online Access:http://zmj.zsmu.edu.ua/article/view/204917/205982
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850166974317854720
author D. I. Kebalo
N. P. Miroshnykova
O. P. Shershniova
S. M. Pashchenko
E. D. Zvantseva
author_facet D. I. Kebalo
N. P. Miroshnykova
O. P. Shershniova
S. M. Pashchenko
E. D. Zvantseva
author_sort D. I. Kebalo
collection DOAJ
description The purpose of this work is to determine the optimal markers for clarifying the degree of proliferative activity in benign breast lesions, which can be used in surgical treatment planning. Materials and methods. The immunocytochemical results of tumor proliferation marker (Ki-67), cancer-embryonic antigen (CEA), matrix metalloproteinase-9 (MMP-9) and vascular endothelial growth factor (VEGF) expression were studied in biopsy samples collected from 108 patients with benign breast lesions and 49 patients with breast cancer. Results. It was found that the proliferative processes rising was accompanied by an increase in the number of patients with expression of Ki-67 to 28.0 %, CEA to 44.0 %, VEGF to 80.0 %, and a decrease in the number of patients with MMP-9 expression from 75.0 % to 36.4 %. Among patients with breast cancer, cells expressing Ki-67 were observed in 36.8 %, MMP-9 in 20.7 %, CEA in 36.4 %, VEGF in 48.3 %. The results indicate the presence of a neoplastic potential in benign lesions and its enhancement with an increase in proliferative properties. Conclusions. This diagnostic method can be used to determine the malignant potential in benign breast lesions and for therapeutic decision making.
format Article
id doaj-art-e4d33fdeee1f4c17872265e2f196ae53
institution OA Journals
issn 2306-4145
2310-1210
language English
publishDate 2020-06-01
publisher Zaporizhzhia State Medical and Pharmaceutical University
record_format Article
series Zaporožskij Medicinskij Žurnal
spelling doaj-art-e4d33fdeee1f4c17872265e2f196ae532025-08-20T02:21:18ZengZaporizhzhia State Medical and Pharmaceutical UniversityZaporožskij Medicinskij Žurnal2306-41452310-12102020-06-0122334434910.14739/2310-1210.2020.3.204917Diagnosis of precancerous lesions of the breastD. I. Kebalo0N. P. Miroshnykova1O. P. Shershniova2S. M. Pashchenko3E. D. Zvantseva4CRDC COMREC, Zaporizhzhia, Ukraine CRDC COMREC, Zaporizhzhia, UkraineSI “Zaporizhzhia Medical Academy of Postgraduate Education of the Ministry of Health of Ukraine” Zaporizhzhia Regional Clinical Oncology Hospital, UkraineCRDC COMREC, Zaporizhzhia, UkraineThe purpose of this work is to determine the optimal markers for clarifying the degree of proliferative activity in benign breast lesions, which can be used in surgical treatment planning. Materials and methods. The immunocytochemical results of tumor proliferation marker (Ki-67), cancer-embryonic antigen (CEA), matrix metalloproteinase-9 (MMP-9) and vascular endothelial growth factor (VEGF) expression were studied in biopsy samples collected from 108 patients with benign breast lesions and 49 patients with breast cancer. Results. It was found that the proliferative processes rising was accompanied by an increase in the number of patients with expression of Ki-67 to 28.0 %, CEA to 44.0 %, VEGF to 80.0 %, and a decrease in the number of patients with MMP-9 expression from 75.0 % to 36.4 %. Among patients with breast cancer, cells expressing Ki-67 were observed in 36.8 %, MMP-9 in 20.7 %, CEA in 36.4 %, VEGF in 48.3 %. The results indicate the presence of a neoplastic potential in benign lesions and its enhancement with an increase in proliferative properties. Conclusions. This diagnostic method can be used to determine the malignant potential in benign breast lesions and for therapeutic decision making.http://zmj.zsmu.edu.ua/article/view/204917/205982mammary glandbiochemical tumor markersimmunocytochemistry
spellingShingle D. I. Kebalo
N. P. Miroshnykova
O. P. Shershniova
S. M. Pashchenko
E. D. Zvantseva
Diagnosis of precancerous lesions of the breast
Zaporožskij Medicinskij Žurnal
mammary gland
biochemical tumor markers
immunocytochemistry
title Diagnosis of precancerous lesions of the breast
title_full Diagnosis of precancerous lesions of the breast
title_fullStr Diagnosis of precancerous lesions of the breast
title_full_unstemmed Diagnosis of precancerous lesions of the breast
title_short Diagnosis of precancerous lesions of the breast
title_sort diagnosis of precancerous lesions of the breast
topic mammary gland
biochemical tumor markers
immunocytochemistry
url http://zmj.zsmu.edu.ua/article/view/204917/205982
work_keys_str_mv AT dikebalo diagnosisofprecancerouslesionsofthebreast
AT npmiroshnykova diagnosisofprecancerouslesionsofthebreast
AT opshershniova diagnosisofprecancerouslesionsofthebreast
AT smpashchenko diagnosisofprecancerouslesionsofthebreast
AT edzvantseva diagnosisofprecancerouslesionsofthebreast